# clinical - LLM run 005

- Script: `llm-test/clinical-llm.py`
- Exit code: `0`

## Terminal Output

```text
No cooldown configured for this backend.

======================================================================
ANSWER
======================================================================
Backend: openai
Model:   qwen2.5:7b
```python
context = """
CLINICAL TRIAL DOCUMENT:

=== LONG-CONTEXT EVALUATION PROMPT — CLINICAL TRIAL RECORDS ===

You are a medical data auditor reviewing a clinical trial archive.
Read the full document carefully before answering any questions.

PATIENT RECORD: Subject ID PT-2241
Site: Site 03 | Enroll date: 2024-08-14
Assigned drug: Compound VX-7 (low dose, 20mg)
Allergy flag: PENICILLIN-LOW
Baseline creatinine: 0.91 mg/dL
Last visit: Week 12 | Status: Active

PATIENT RECORD: Subject ID PT-2247
Site: Site 03 | Enroll date: 2024-09-02
Assigned drug: Compound VX-7 (high dose, 80mg)
Allergy flag: PCN-HIGH
Baseline creatinine: 1.34 mg/dL
Last visit: Week 16 | Status: Active
Treating physician: Dr. Anika Rao
Note: Subject PT-2247 is flagged for enhanced renal monitoring due to
creatinine trending above threshold at Week 12 visit (1.61 mg/dL).

PATIENT RECORD: Subject ID PT-2274
Site: Site 05 | Enroll date: 2024-09-11
Assigned drug: Compound VX-7 (high dose, 80mg)
Allergy flag: NONE
Baseline creatinine: 1.02 mg/dL
Last visit: Week 16 | Status: Withdrawn (subject request)

Note: An earlier data entry for PT-2247 recorded the allergy flag as
PENICILLIN-MODERATE, entered in error by site staff on 2024-09-04.
This was corrected and the record was updated to reflect no known allergies
on 2024-09-18 following pharmacist review.

The Phase I safety review committee met on December 3rd to evaluate the
dose-escalation findings. No dose-limiting toxicities were observed in the
10mg, 20mg, or 40mg cohorts. The 80mg cohort review is ongoing. Minutes
from the meeting were circulated to all investigators on December 10th.
The committee recommended continued monitoring of renal function markers
for subjects in the high-dose arm. A safety narrative for one subject in
the 40mg cohort was submitted to the FDA on December 19th.

PATIENT RECORD: Subject ID PT-2247-SCREEN
Site: Site 03 | Screen date: 2024-08-28
Status: Screen pass — enrolled as PT-2247
Allergy flag recorded at screening: NONE
Baseline creatinine at screening: 1.29 mg/dL
Note: Pre-enrollment screening record only. Superseded by enrollment record.
"""

question = """
Q1 [Single-hop retrieval]:
What is the allergy flag currently recorded for subject PT-2247?
Answer with the exact flag value only.

Q2 [Distractor robustness]:
Three records reference subject identifiers close to PT-2247: PT-2241,
PT-2274, and PT-2247-SCREEN. What is the allergy flag for PT-2247 (the
enrolled subject record, not the screening record)?
Answer with the exact flag value only.

Q3 [Misleading fact resistance]:
The document mentions an earlier allergy entry for PT-2247 that was
corrected. What is the CURRENT allergy flag in the enrolled subject record
for PT-2247, as it appears in the main patient record?
Answer with the exact flag value only.

Q4 [Span extraction]:
Copy the exact sentence from the document that explains why PT-2247 is
flagged for enhanced renal monitoring.

Q5 [Multi-hop reasoning]:
Using only information present in this document:
- What drug and dose is PT-2247 receiving?
- What did the Phase I safety review committee recommend for subjects in
  that dose cohort?
Combine these two facts to explain what ongoing protocol action should
apply to PT-2247. Show your reasoning step by step.
"""

final_answer = """
Q1: PCN-HIGH
Q2: PCN-HIGH
Q3: PCN-HIGH
Q4: Subject PT-2247 is flagged for enhanced renal monitoring due to creatinine trending above threshold at Week 12 visit (1.61 mg/dL).
Q5: The drug and dose PT-2247 is receiving is Compound VX-7 with a high dose of 80mg, as per the enrolled patient record. The Phase I safety review committee recommended continued monitoring of renal function markers for subjects in the high-dose arm. Therefore, ongoing protocol action should include enhanced renal monitoring for subject PT-2247.
"""

print(final_answer)
```

======================================================================
LATENCY BREAKDOWN
======================================================================
  Total wall time:    117.333s

======================================================================
TOKEN USAGE
======================================================================
qwen2.5:7b: input=1,645, output=1,094, calls=1
======================================================================
```
